Healthy Subjects
Conditions
Keywords
probiotic, lactobacillus paracasei, calcium, faecal microbiota, cholesterol metabolism
Brief summary
The study was conducted to investigate the effect of the probiotic L. paracasei LPC 37 alone or in combination with a calcium supplement of the human microbiota and further physiological parameters.
Detailed description
Animal studies suggest that calcium beneficially influence the microbiota in the gut. This effect of calcium is due to the formation of amorphous calcium phosphate, which has the ability to bind bile acids and other cytotoxic substances in the gut. The precipitation of the cytotoxic substances leads to a less aggressive environment in the gut and might be stimulate the adhesion of the microbiota. Thirty-two healthy men and women participated in a placebo-controlled, double-blind and cross over human study. The participants were randomly divided into two groups. All probands consumed a probiotic drink for four weeks (10e+10 CFU/d). Additionally, one group consumed a pentacalcium phosphate-enriched bread (1 g Ca/d) and the other group consumed a bread without pentacalcium phosphate. After a two-week wash-out and a two-week placebo period the invention changed for another four weeks (cross over). At the end of each intervention and placebo period, subjects consumed a defined diet for three days. Furthermore, there was a three-day quantitative stool and urine collection and a fasting venous blood sample was taken.
Interventions
the subjects consumed for 4 weeks a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 and a bread enriched with 1 g pentacalcium phosphate per day
the subjects consumed a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 for 4 weeks
the subjects consumed a yoghurt drink without L. paracasei LPC 37 and a bread without pentacalcium phosphate
Sponsors
Study design
Eligibility
Inclusion criteria
* healthy subjects * blood cholesterol concentration \> 5 mmol/l
Exclusion criteria
* pregnancy, lactation * intake of dietary supplements * intake of prebiotics and probiotics * chronic diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| faecal microbiota, cholesterol metabolism | 4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| mineral status, immunological parameters | 4 weeks |
Countries
Germany